Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Tweaks IND Clinical Hold Policy As Number Of Holds Rises

Executive Summary

Clinical holds by the US FDA have risen 36% since 2014.


Related Content

Deal Watch: Vertex Selects First Candidate Under CRISPR Gene-Editing Collaboration
Dynavax's Hep B Vaccine Finally Clears US FDA With Clean Label But Larger Safety Study
What Was On Hold Is New Again As Impact Raises $22.5m For Fedratinib
A Cellectis Trial Death Points To Challenges Ahead For CAR-T
FDA Clinical Hold Hits Keytruda Multiple Myeloma Studies
Merck’s Heplisav Gets FDA Clinical Hold


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts